NexImmune, Inc., a biopharmaceutical company, has filed Post-Effective Amendment No. 1 with the U.S. Securities and Exchange Commission (SEC) on August 27, 2024, to deregister all unsold shares of common stock previously registered under three separate Form S-8 registration statements. These statements were associated with the company's equity incentive plans from 2017, 2018, and 2021. The deregistration follows a 1-for-25 reverse stock split executed on October 18, 2023, and is in line with the stockholders' approval of the company's dissolution, liquidation, and winding-up as disclosed in a Form 8-K filed on August 15, 2024. The company has terminated all offerings of its securities and has removed from registration all securities that remain unsold as of the filing date.

NexImmune, Inc., a biopharmaceutical company, has filed Post-Effective Amendment No. 1 with the U.S. Securities and Exchange Commission (SEC) on August 27, 2024, to deregister all unsold shares of common stock previously registered under three separate Form S-8 registration statements. These statements were associated with the company's equity incentive plans from 2017, 2018, and 2021. The deregistration follows a 1-for-25 reverse stock split executed on October 18, 2023, and is in line with the stockholders' approval of the company's dissolution, liquidation, and winding-up as disclosed in a Form 8-K filed on August 15, 2024. The company has terminated all offerings of its securities and has removed from registration all securities that remain unsold as of the filing date.